Mitogen/extracellular signal-regulated kinase (MEK) inhibitors have been tested in clinical trials for treatment of intracranial neoplasms, including glioblastoma (GBM), but efficacy of these drugs has not yet been demonstrated. The blood-brain barrier (BBB) is a major impediment to adequate delivery of drugs into the brain and may thereby also limit the successful implementation of MEK inhibitors against intracranial malignancies. The BBB is equipped with a range of ATP-dependent efflux transport proteins, of which P-gp (ABCB1) and BCRP (ABCG2) are the two most dominant for drug efflux from the brain. We investigated their impact on the pharmacokinetics and target engagement of a panel of clinically applied MEK inhibitors, in order to select the most promising candidate for brain cancers in the context of clinical pharmacokinetics and inhibitor characteristics. To this end, we used in vitro drug transport assays and conducted pharmacokinetic and pharmacodynamic studies in wildtype and ABC-transporter knockout mice. PD0325901 displayed more promising characteristics than trametinib (GSK1120212), binimetinib (MEK162), selumetinib (AZD6244), and pimasertib (AS703026): PD0325901 was the weakest substrate of P-gp and BCRP in vitro, its brain penetration was only marginally higher in Abcb1a/b;Abcg2 2/2 mice, and efficient target inhibition in the brain could be achieved at clinically relevant plasma levels. Notably, target inhibition could also be demonstrated for selumetinib, but only at plasma levels far above levels in patients receiving the maximum tolerated dose. In summary, our study recommends further development of PD0325901 for the treatment of intracranial neoplasms.
Introduction
The mitogen-activated protein kinase (MAPK) pathway has emerged as a druggable target in various primary and secondary intracranial neoplasms. First, the vast majority (85%) of glioblastomas (GBM) is characterized by a hyper-activated MAPK pathway. 1 Second, IDH wildtype low-grade gliomas often have alterations in NF1, EGFR, and PTPN11. 2 Third, pediatric gliomas such as diffuse intrinsic pontine glioma, non-brainstem high-grade glioma, and pleomorphic xanthoastrocytoma frequently harbor alterations in the NTRK receptor family and MET. 3, 4 Finally, cancers that frequently metastasize to the brain, e.g., melanoma and non-small cell lung cancer, are known to carry MAPK pathway activating alterations such as the BRAF V600E and KRAS G12 mutation. 5, 6 The MAPK pathway comprises two isotypes of MEK (MEK1 and MEK2) that are 86% homologous in the catalytic domain and have narrow substrate specificities for ERK1 and ERK2. All MEK inhibitors that are now under development are highly specific, because they do not bind to the kinase domain, but to a hydrophobic pocket that is unique for MEK1/2. 8 As a consequence, there is great structural overlap between the MEK inhibitors originating from different pharmaceutical companies ( Fig. 1 ).
Although MEK inhibitors may be important for treating intracranial tumors, there are only very few clinical studies ongoing that specifically address the treatment of intracranial tumors, including glioblastoma. Importantly, these malignancies are all to some degree protected by the blood-brain barrier (BBB). The BBB is formed by the brain endothelial cells (BECs). Drug trafficking of hydrophilic substances is restricted by the presence of tight junctions, absence of fenestrae and low pinocytic activity of BECs. Uptake of nutrients is mediated by selective uptake carriers, such as glucose by Glut-1 (SLC2A1), whereas other compounds depend on passive diffusion. Although more lipophilic substances may enter the brain relatively easily by passive diffusion, this is frequently restricted by ATP-binding cassette (ABC) transporters located at the apical membrane of BECs. 9 In particular Pgp (ABCB1/MDR1) and BCRP (ABCG2) are the two most dominant drug efflux transporters in the BBB where they restrict the brain penetration of numerous anticancer agents, including many of the novel small molecule targeted inhibitors. [10] [11] [12] Importantly, this impaired brain penetration can attenuate target engagement and thereby therapeutic efficacy against intracranially located tumors. [13] [14] [15] As it is thus of paramount importance to select the most appropriate candidate drugs for treatment of intracranial neoplasms with respect to their brain penetration, we have first determined the substrate affinities of PD0325901, trametinib (GSK1120212), binimetinib (MEK162), selumetinib (AZD6244), and pimasertib (AS703026) for P-gp and BCRP by in vitro transwell assays. Based on these data, we investigated the brain penetration of PD0325901, selumetinib and pimasertib in wildtype (WT) and transporter knockout mice and intracranial target engagement in WT mice following oral administration of drugs at doses that result in clinically relevant plasma levels. 
Methods

Drugs
Concentration equilibrium transport assays
Concentration equilibrium transport assays (CETAs) were performed as described previously. 19 In short, MDCK or LLC cells were seeded onto Transwell microporous polycarbonate membrane filters (Costar Corning, Corning, NY) and allowed to grow into a monolayer. The experiment was started by replacing medium in the apical and basolateral compartment by MEK inhibitor containing medium (100 nM or 1 lM) and samples were taken from both compartments at specific time points. When appropriate, specific transport was inhibited using the Pgp inhibitor zosuquidar (5 lM) or the dual P-gp/BCRP inhibitor elacridar (5 lM). Monolayer integrity was assessed by translocation of Carboxyl-[ 14 C]-inulin. Wells demonstrating leakiness exceeding 1.5% per hour were excluded from analysis.
PD0325901, selumetinib and pimasertib samples were mixed with four parts of acetonitrile. After centrifugation, the supernatant was threefold diluted in water and the drug concentration was measured by high performance liquid chromatography (HPLC) with UV detection at 275 nm (PD0325901), 257 nm (selumetinib), or 282 nm (pimasertib) using a GraceSmart RP18
What's new? Almost all brain cancers-adult and pediatric, primary and secondary-harbor an overactivated MAPK pathway. Clinical studies are still few, but the key role and downstream location of MEK render MEK inhibitors of potential interest for the treatment of intracranial neoplasms. However, the blood-brain barrier is a major impediment to the brain penetration and intracranial efficacy of drugs. To support successful clinical implementation of MEK inhibitors, the authors investigated the brain penetration of five clinically applied MEK inhibitors in mice, and selected PD0325901 as the candidate with the most promising pharmacokinetic and pharmacodynamics properties for the treatment of intracranial tumors.
5 mm column (Grace, Deerfield, IL). The mobile phases comprised of 0.1% (v/v) formic acid in water and 80% (v/v) methanol in water. Elution was done at different ratios (v/v) for PD0325901 (25/75), selumetinib (15/85), and pimasertib (17.5/ 82.5) delivered at a flow rate of 0.2 ml/min. Data analysis was performed using Chromeleon V R 6.80 software (Dionex, Sunnyvale, CA).
Binimetinib and trametinib were extracted from medium using ethyl acetate for liquid-liquid extraction and buparlisib as internal standard. Samples were reconstituted in acetonitrile: water (30:70 v/v) and measured in a LC-MS/MS setup consisting of an Ultimate 3000 LC System (Dionex) and an API 3000 mass spectrometer (AB Sciex, Framingham, MA). Separation was performed on a ZORBAX Extend-C18 column (Agilent Technologies, Santa Clara, CA). Mobile phase A (0.1% formic acid in water) and B (methanol) was used in a 5 min gradient from 30%B to 95%B maintained for 3 min followed by re-equilibration at 30%B. Multiple reaction monitoring (MRM) ion pairs were 443.0/381.0 (binimetinib) and 616.2/491.2 (trametinib). Data was analyzed using Analyst V R 1.5.1 software (AB Sciex). 
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Animals
All animal housing and studies were conducted according to national law and institutional guidelines and approved by the animal experimental committee. Housing environment was temperature-controlled, on a 12 hr light/dark cycle and food and water were provided ad libitum.
Pharmacokinetic studies
Pharmacokinetic studies were conducted using WT, Abcg2
, and Abcg2;Abcb1a/b 2/2 FVB mice. All knockout mouse strains were previously generated and characterized within the Netherlands Cancer Institute. [20] [21] [22] PD0325901, selumetinib and pimasertib were either dissolved in DMSO and administered i.v. at a dose of 5 mg/kg or given p.o. at various doses in a formulation consisting of DMSO:Cremophor EL:water (1:1:8). Blood was collected from the tip of the tail at serial time points, while terminal bleeding was done by cardiac puncture under isoflurane anesthesia, followed by tissue collection. Plasma was obtained by centrifugation (5 min, 5,000 rpm, 48C). Tissues were weighed and homogenized using a FastPrep V R -24 (MP-Biomedicals, NY) in 1% (w/v) bovine serum albumin in water. Samples were analyzed using an LC-MS/MS method as described for trametinib and binimetinib CETAs. Palomid 529 was used as internal standard for PD0325901 analysis, while selumetinib and pimasertib were used as reciprocal internal standards. MRM ion pairs were 483.1/249.1 (PD0325901), 459.1/397.0 (selumetinib), and 432.1/214.1 (pimasertib).
Western blotting
Brain tissues were homogenized in complete RIPA buffer containing phosphatase inhibitors. Primary antibodies used in our study are phospho-Erk1/2 (Erk1 T202/204 and Erk2 T183/
Y185
) and total Erk1/2 (C16) (Santa Cruz Biotechnology, Santa Cruz, CA). Blots were quantified using Image Lab v5.2.1 (Bio-Rad Laboratories Inc., Hercules, CA).
Pharmacokinetic and statistical analysis
Concentration equilibrium transport assay results were analyzed using the General linear model repeated measures procedure of SPSS (v20; SPSS Inc, Chicago, IL) as described previously. 12 For in vivo experiments one-way analysis of variance and post hoc Tukey was performed. Differences were considered statistically significant when p < 0.05.
Results
Selumetinib is transported and restricted from the brain by P-gp and BCRP ATP-binding cassette-transporter knockout mice and concentration equilibrium transport assays (CETAs) together form a comprehensive set of experiments to investigate the impact of P-gp and BCRP on the brain penetration of small molecules and have been extensively used for these purposes in the past. [11] [12] [13] 23, 24 Here, we used these methods to study a panel of MEK inhibitors (Fig. 1) . First, selumetinib was demonstrated to be a substrate of human and murine P-gp (ABCB1/MDR1) and BCRP (ABCG2). Species differences in substrate affinities between murine and human transport proteins may exist. However, selumetinib was efficiently transported by cells transduced with either transporter, but much less by their untransduced (parent; PK1) counterparts (Figs. 2a and 2b, Table 1 ). Near-complete transport inhibition by either zosuquidar or elacridar in the transduced cells confirmed that P-gp and BCRP were mostly responsible for the observed drug translocation. The translocation of selumetinib in the LLC-PK1 cells was not reduced by zosuquidar, indicating that this might be caused by another transporter that seems absent in the Mdr1a cells. The residual translocation in the MDCK-Bcrp1 cells in the presence of elacridar suggests incomplete inhibition of Bcrp1. Pharmacokinetic studies revealed a marked impact of P-gp and BCRP on selumetinib brain penetration. Whereas plasma levels were similar in wildtype and transporter knockout mice, the brain concentration of selumetinib was 3.5-fold increased in Abcb1a/b;Abcg2 2/2 mice following i.v. administration (Fig,  2c , Table 1 ). Interestingly, neither single knockout mouse strain demonstrated any increased brain penetration, indicative of redundancy between P-gp and BCRP as has been observed for various other compounds. 11, 24, 25 The brain-to-plasma ratio was only about 0.02, which is close to the fraction of blood in brain samples. The selumetinib brain-to-plasma ratio increased in Abcb1a/b;Abcg2 2/2 mice, but remained very poor (0.06). Since small molecules are mostly administered p.o. in preclinical efficacy studies and clinical trials, we sought to determine the brain concentration that could be reached in wildtype mice following oral administration of a range of dose levels that yielded clinically relevant plasma concentrations. A dose-dependent increase in both plasma and brain selumetinib concentration was observed 1 hr after doses ranging from 1 to 5 mg/kg, in all cases yielding a brain-toplasma ratio similar to that following i.v. administration (Fig,  2d , Table 1 ). Unfortunately however, dose levels higher than 1 mg/kg resulted in a plasma concentration above clinically achievable levels and thus 15 ng/g seems to be highest feasible brain concentration in the clinic (Table 1) .
Pimasertib is very efficiently transported by P-gp and BCRP, profoundly impacting its brain penetration Pimasertib displayed a similar pattern of results as selumetinib, although the extent and efficiency of transport was even more pronounced as CETAs showed very efficient translocation in all transduced sublines. Translocation was inhibited by zosuquidar in LLC-MDR1 cells, but not in LLC-PK1 (Figs. 3a and 3b , Table  1 ), again suggesting the presence of an alternative transporter. Elacridar appears to be unable to inhibit transport by Bcrp1. In vivo, a 4.4-fold increased brain concentration was found in Abcb1a/b;Abcg2 2/2 mice compared to wildtype mice, while no difference was seen in single knockout mice due to transporter redundancy (Fig. 3c, Table 1 ). Importantly, already in wildtype mice pimasertib demonstrated a quite reasonable brain-toplasma ratio of 0.6, which was further increased to 2.4 in 
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2/2 mice. The brain-to-plasma ratio was about twofold lower after oral administration. Oral administration in wildtype mice indicated that 75 ng/g is likely the highest clinically achievable brain concentration since 2 mg/kg was the highest dose at which the plasma concentration did not exceed those in patients receiving the clinical maximum tolerated dose (MTD) (Fig. 3d , Table 1 ).
PD0325901 is a weak substrate of P-gp and BCRP and reaches reasonable brain levels in wildtype mice
Of all five MEK inhibitors that were analyzed, PD0325901 was least efficiently transported in CETAs, although it still exhibited substrate affinity toward P-gp and BCRP (Figs. 4a and 4b, Table 1 , Supporting Information Fig. 1 ). Following i.v. administration, PD0325901 has a similar brain-to-plasma ratio as pimasertib (0.6). The brain penetration of PD0325901 is the least restricted by P-gp and BCRP as it is twofold higher in Abcb1a/b;Abcg2 2/2 mice (Fig. 4c, Table 1 ). Finally, PD0325901 achieved the highest brain concentration (82 ng/g) following oral administration of a dose that resulted in a clinically feasible plasma concentration, despite a strongly reduced brain-to-plasma ratio compared to i.v. administration (Fig.  4d , Table 1 ). 
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PD0325901 and pimasertib achieve the highest clinically relevant target inhibition
To understand the impact of brain pharmacokinetics on therapeutic efficacy it is imperative to assess target engagement of selective inhibitors. To this end, phosphorylation of ERK1/ 2, directly downstream of MEK, was analyzed in the brains of the mice in the pharmacokinetic studies receiving various oral doses of the MEK inhibitors. Target inhibition was dosedependent for all inhibitors, with the greatest inhibition achieved by 5 mg/kg of selumetinib (Fig. 5, Table 1 ). However, as mentioned previously, the highest dose levels that yielded plasma concentrations that are clinically achievable in patients were 1 mg/kg for selumetinib, 2 mg/kg for pimasertib, and 5 mg/kg for PD0325901 (Table 1) . When comparing 
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these dose levels, pimasertib and PD0325901 achieved a better target inhibition levels than selumetinib. Both MEK inhibitors achieved approximately 50% inhibition of both ERK1 and ERK2.
Discussion
In recent years, characterization of the genomic landscapes of various primary and secondary intracranial neoplasms has demonstrated that MAPK pathway overactivation is a common hallmark of these tumors. [1] [2] [3] 5, 6 The potential importance of MEK inhibitors for the treatment of intracranial neoplasms calls for careful selection of the most appropriate candidate inhibitor, since focusing resources on the MEK inhibitor with the greatest potential to achieve a clinical benefit would ensure the most rapid clinical implementation if efficacy can be confirmed. In our study, we select PD0235901 as the most promising candidate out of a panel of five MEK inhibitors that are in clinical development (Table 1) .
Only very few clinical studies investigating MEK inhibitors against intracranial tumors are ongoing or have been conducted. The clinical development of MEK inhibitors is slightly more advanced for secondary brain tumors (e.g., Clinicaltrials.-gov identifiers NCT02015117, NCT01245062, NCT01693068) than for primary brain tumors (e.g., Clinicaltrials.gov identifiers NCT01089101, NCT02285439, NCT02124772). MEK inhibitors have found their place in anticancer therapy. For example, a phase III trial on trametinib in patients with BRAF V600E -postive metastatic melanoma demonstrated improved survival for metastatic patients. 26 However, in this study patients with prior brain metastases were excluded from the analysis. In general, intracranial metastases are a negative prognostic factor, as a consequence of the more advanced disease state and the complications of drug delivery through the BBB. As has been demonstrated in mice, P-gp and BCRP at the BBB can limit the access and thus efficacy of anticancer agents against tumors in the brain, whereas genetically similar extracranial tumors are responsive. 27 Despite the similarities in molecular structures of the different MEK inhibitors, there are major distinctions in their affinity for P-gp and BCRP and the ability to permeate the BBB, underscoring the need to make a careful choice. Based on our preclinical data, we demonstrate that brain access of selumetinib is efficiently restricted (brain-to-plasma ratio of only 0.02-0.06) and results in just a marginal inhibition of intracranial MEK at clinically achievable plasma concentrations. In fact, the selumetinib brain-to-plasma ratio in WT mice is not much higher than the value that we would obtain when all drug in the sample originates from blood in the sample, 28 suggesting that selumetinib is near-incapable of penetrating the BBB. In contrast, both pimasertib and PD0325901 displayed much better pharmacokinetic/pharmacodynamic (PK/PD) characteristics, although PD0325901 outperformed pimasertib in some respects. Of all five MEK inhibitors that were analyzed by in vitro transwell assays, PD0325901 was the weakest substrate of P-gp and BCRP (Table 1, Figs. 2a and 2b, 3a and 3b, 4a and 4b and Supporting Information Fig. 1 ), whereas the affinities of the other compounds were quite similar. Based on these, we also took pimasertib and PD0325901 to in vivo studies with ABC-transporter knockout mice that showed that P-gp and Bcrp1 alone can reduce brain entry to the level in WT mice. Intriguingly, a recent study with trametinib reports that the brain penetration of this compound in WT mice is only 5-10% of the levels in knockout mice but in this case only Abcb1 is limiting drug entry into the brain (Table 1) . 29 Pimasertib and PD0325901 achieved similar intracranial MEK inhibition levels at clinically feasible plasma concentrations, although the inhibition level by PD0325901 might be slightly underestimated since the highest PD0325901 plasma level achieved in our study was lower than the C max of patients receiving the MTD (660 vs. 840 ng/mL). 30 Even though target inhibition was similar for pimasertib, PD0325901 could still be considered a more favorable candidate for the following three reasons. First, because of its lower affinity for P-gp and BCRP, PD0325901 could be less prone to ABC transporter-mediated acquired resistance. Second, it has a lower IC 50 against MAPK pathway overactivated cancer cell lines (Table 1) , making it intrinsically more effective against cancer cells. [31] [32] [33] Third, PD0325901 demonstrates a considerably smaller inter-patient variability in plasma PK profiles, with a coefficient of variation in C max following oral administration of 30% for PD0325901 and 100% for pimasertib. 30, 34 A more homogeneous PK profile among patients is clearly more favorable for treatment accuracy, especially when considering that patients with the lowest exposure to pimasertib (C max of 70 ng/mL) will have plasma levels above the intended target inhibition concentration for only a very short duration. The much higher inter-patient variability of pimasertib may indicate a more problematic uptake after oral intake. In line with this reasoning, pimasertib reaches a fourfold lower C max compared to PD0325901, even though the daily intake is 1.5-fold higher (45 mg QD vs. 15 mg BID). Just like many other MEK inhibitors that have been tested in the clinic, ocular toxicity was the dose limiting toxicity for PD0325901, raising the question of a possible class-effect of these targeted agents. 30, 35 However, the ocular toxicity was manageable and reversible at the MTD of 15 mg BID when given in a schedule of 5 days on/2 days off for 3 weeks followed by 1 week off. 36 Importantly, the trough plasma levels of PD0325901 (170 ng/mL) remained well over the intended target concentration (16.5 ng/mL), despite this dosing schedule containing days off the drug. PD0325901 is currently in clinical trials for treatment of extracranial solid tumors (NCT02022982, NCT02510001, NCT02039336).
In conclusion, in vitro and in vivo studies demonstrate that among a panel of five MEK inhibitors that are in clinical development, PD0325901 possesses the most favorable pharmacokinetic and pharmacodynamics properties to reach efficacy in the brain. These characteristics make PD0325901 the most promising candidate for further development as treatment for intracranial malignancies.
